Business Context and Reporting Period
Company: STAAR Surgical Company
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2004
Business Overview: STAAR Surgical develops, manufactures, and distributes ophthalmic products for cataract, refractive, and glaucoma surgery. The company operates as a single business segment, with cataract products accounting for approximately 90.4% of revenues in 2004. Key products include foldable intraocular lenses (IOLs), the Visian ICL (refractive surgery), and the AquaFlow glaucoma device.
Key Financial Metrics
| Metric | 2004 (in thousands) | 2003 (in thousands) |
|---|---|---|
| Total Revenues | $51,685 | $50,458 |
| Gross Profit | $26,143 | $27,837 |
| Gross Margin | 50.6% | 55.2% |
| Operating Loss | $(10,158) | $(6,525) |
| Net Loss | $(11,332) | $(8,357) |
| Loss Per Share (Basic/Diluted) | $(0.58) | $(0.47) |
| Cash and Cash Equivalents (Year End) | $4,187 | $7,286 |
| Short-Term Investments | $5,125 | $0 |
| Working Capital | $19,103 | $15,883 |
| Total Debt (Notes Payable) | $3,004 | $2,950 |
Research & Development: $6,246 (12.1% of revenue), a 22% increase from 2003, driven by regulatory compliance costs and product redesigns.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 2.4% to $51.7 million. This growth was driven by a 37.6% increase in international sales of the Visian ICL and strong sales of the new preloaded silicone lens injector system.
- U.S. Sales Decline: U.S. sales declined 7.8% due to a contraction in the silicone IOL market (surgeons shifting to acrylic), negative market perception from FDA compliance issues, and supply interruptions during injector redesigns.
- Margin Compression: Gross margin decreased from 55.2% to 50.6%. Factors included increased manufacturing engineering costs, inventory provisions, higher unit costs from process changes, and a shift in product/geographic mix.
- Increased Expenses: Operating expenses rose significantly. R&D increased by $1.1 million (22%) due to FDA audit preparation and injector redesigns. Marketing and selling expenses increased by $793,000, largely due to foreign exchange fluctuations.
- Financing Activity: The company raised approximately $11.6 million in net proceeds from a private placement of 2 million shares of common stock in June 2004.
Guidance, Outlook, Risks, and Contingencies
Going Concern Warning: The company's independent auditors (BDO Seidman, LLP) issued a report with an explanatory paragraph stating there is substantial doubt about the company's ability to continue as a going concern. This is due to recurring losses, negative cash flows, and an accumulated deficit of $60.5 million.
Liquidity and Financing: Current working capital is insufficient to satisfy anticipated requirements for fiscal 2005. The company expects to continue experiencing negative cash flows until FDA issues are resolved and the ICL is approved in the U.S. The company is actively seeking additional financing and exploring strategic options.
Regulatory Risks (FDA):
- The company received FDA Warning Letters (Dec 2003, April 2004) and Form 483 Inspectional Observations (Sept 2004) regarding manufacturing and quality assurance deficiencies at its Monrovia, California facility.
- Resolution of these issues is a prerequisite for FDA approval of the Visian ICL in the United States. Until resolved, approval is unlikely, and the FDA may take further actions including product seizure or injunction of the facility.
Legal Proceedings: Multiple consolidated class action lawsuits were filed in late 2004 alleging securities fraud regarding false statements about intraocular lenses and failure to disclose product problems. The company intends to vigorously defend these suits.
Outlook: Management plans to reduce operating expenses by $3.0 million annually through reduced consultant usage and sales force reductions. However, continued declines in U.S. sales could offset these savings.
Investor Verification Checklist
- Going Concern Status: Verify the company's ability to secure additional financing to fund operations through 2005 given the auditor's "substantial doubt" qualification.
- FDA Resolution: Monitor the status of the FDA's review of the company's corrective action plans regarding the Warning Letters and 483 Observations, as this blocks U.S. ICL approval.
- U.S. Market Share: Assess the trend of declining U.S. silicone IOL sales and the effectiveness of the new Collamer IOL and injector systems in reversing this trend.
- Legal Exposure: Track the progress of the consolidated securities class action lawsuits and potential settlement costs.
- Cash Burn Rate: Review quarterly cash flow statements to ensure the $9.3 million in cash and short-term investments (as of year-end 2004) is sufficient to cover the projected negative operating cash flows.